Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
NV

NASDAQ · NVNO

enVVeno Medical Corporation

Healthcare · Medical - Devices

$7.00

Down-$0.17 (-2.43%)

Updated Nov 5, 2026, 2:36 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.27M
P/E ratio
-0.33
Dividend yield
0.00%
52-week range
$6.52 – $13.44
Volume
63.76K
Avg. volume
586.22K

Price performance · NVNO

NVNO price history

1M range · 0 trading sessions · Daily adjusted prices

NVNO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest NVNO news

The latest Smart Investors Daily articles mentioning NVNO.

Stock researchCompany · Overview

NVNO research

Overview

Company profile and research snapshot.

Company profile

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study

pivotal study of the first-in-class enVVe non-surgical replacement venous valve on track to begin before year endCash and investments of $18.5 million expected to fund operations into Q4 2027, including the planned initiation of TAVVEIRVINE, CA / ACCESS Newswire / October 30, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the third quarter ended September 30, 2026.

Benzinga · Oct 29, 2026

enVVeno Medical Q3 EPS $(6.29) Misses $(3.27) Estimate

enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(6.29) per share which missed the analyst consensus estimate of $(3.27) by 92.35 percent. This is a 21.86 percent increase over losses of $(8.05) per share

Yahoo · Oct 21, 2026

enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman

CEO-led series gives investors the story - straight talk, no B., no corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the next episode hereIRVINE, CA / ACCESS Newswire / October 21, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the release of the third episode of its video series, "WTF with Rob Berman".

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By